Dana–Farber Cancer Institute

Naveris Announces Two Peer-Review Publications Validating NavDx® Performance in Daily Clinical Practice

Retrieved on: 
Thursday, October 12, 2023
Radiology, Health, Surgery, Oncology, Diagnosis, Neoplasm, TTMV, Physician, Ferrandino, Doctor of Philosophy, Research, Dana–Farber Cancer Institute, MD, DNA, CCR, Recurrence, Disease, Human, JAMA, HPV, Literature, Clinical Cancer Research, MRD, Liquid biopsy, OPSCC, Patient, Vaccine

Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance (Hanna, G.J.

Key Points: 
  • Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance (Hanna, G.J.
  • ), published in CCR, is a retrospective observational cohort study involving 543 patients who completed therapy for HPV-driven oropharyngeal squamous cell carcinoma (OPSCC).
  • “NavDx has consistently exhibited stellar performance in well over a dozen peer-reviewed studies following thousands of HPV-driven OPSCC patients.
  • “We congratulate these investigators on their outstanding research, and look forward to our ongoing partnerships with the clinical research community to support bringing NavDx testing to more patients.”

Roswell Park Cancer Innovation SurVaxM Granted FDA Fast Track Designation

Retrieved on: 
Saturday, October 14, 2023
Multimedia, M&T Bank, Priority review, Cancer, Glomus tumor, Food, Doctor of Philosophy, Hope, Research, Roswell Park Comprehensive Cancer Center, Texas Oncology, Ride, Multiple myeloma, Roswell, MD, Fred Hutchinson Cancer Research Center, National Cancer Institute, University, Survival, Disease, FDA, Glioblastoma, Accelerated approval (FDA), Fast track (FDA), NDA, Neurosurgery, Overlook Medical Center, Northwell Health, Journal, FTD, Fast Track, Assistant, PSA, Regulation of tobacco by the U.S. Food and Drug Administration, American Journal of Clinical Oncology, Principal investigator, Prostate cancer, Brain, Patient, Cleveland Clinic, Dana–Farber Cancer Institute, Pharmaceutical industry, Medical imaging, Medical device, Online shopping, DRS, Upstate New York, New York University, Roswell Park

BUFFALO, N.Y., Oct. 14, 2023 /PRNewswire-PRWeb/ -- A promising cancer innovation developed at Roswell Park Comprehensive Cancer Center has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). The designation awarded to MimiVax Inc. provides more extensive and accelerated access to FDA resources for the company's development of the novel cancer immunotherapy SurVaxM, which is now in late-stage trials around the country.

Key Points: 
  • The designation awarded to MimiVax Inc. provides more extensive, accelerated access to FDA resources supporting development of SurVaxM, which originated at Roswell Park.
  • BUFFALO, N.Y., Oct. 14, 2023 /PRNewswire-PRWeb/ -- A promising cancer innovation developed at Roswell Park Comprehensive Cancer Center has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA).
  • From the world's first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide.
  • To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit http://www.roswellpark.org , call 1-800-ROSWELL (1-800-767-9355) or email [email protected] .

MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma

Retrieved on: 
Thursday, October 12, 2023
Priority review, Texas Oncology, UCSF, Fred Hutchinson Cancer Research Center, Disease, FDA, Science in newly industrialized countries, Accelerated approval (FDA), NDA, Overlook Medical Center, Journal, Northwell Health, FTD, Fast Track, NYU, American Journal of Clinical Oncology, Roswell Park, Patient, Cleveland Clinic, Dana–Farber Cancer Institute, Pharmaceutical industry, Medical device, Glioblastoma

BUFFALO, N.Y., Oct. 12, 2023 /PRNewswire/ -- MimiVax, Inc. , a biotechnology company focused on the development of glioblastoma vaccine therapy, announced today that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to MimiVax's SurVaxM vaccine being studied for the treatment of newly diagnosed glioblastoma (nGBM).

Key Points: 
  • BUFFALO, N.Y., Oct. 12, 2023 /PRNewswire/ -- MimiVax, Inc. , a biotechnology company focused on the development of glioblastoma vaccine therapy, announced today that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to MimiVax's SurVaxM vaccine being studied for the treatment of newly diagnosed glioblastoma (nGBM).
  • MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma.
  • MimiVax is focused on completing the Phase 2b SURVIVE study and securing funding necessary to bring SurVaxM through the FDA approval process.
  • "The receipt of Fast Track Designation affirms the importance of new clinical developments of novel therapies to improve the treatment and outcomes for patients with newly diagnosed glioblastoma," said Michael Ciesielski, CEO of MimiVax.

STAT to host fifth annual flagship STAT Summit

Retrieved on: 
Tuesday, October 10, 2023
Parkinson's disease, Eli Lilly and Company, Health, Michael J. Lenardo, State room, Interest, St. Jude Children's Research Hospital, GSK, The Michael J. Fox Foundation, Death, Summit, University of Washington, STAT, University, Medicine, Hospital, Dana–Farber Cancer Institute, Disease, Eli Lilly, Emergency medicine, James R. Downing, Biogen, Science, Priscilla, Violence, University of Chicago Medical Center, Patient, HMS, University of Chicago, Pharmaceutical industry, Management, Nursing

BOSTON, Oct. 10, 2023 /PRNewswire/ -- STAT, the leading media company reporting on health, science, and medicine, is set to host its fifth annual flagship event, the 2023 STAT Summit, later this month. The hybrid event will take place on October 18-19, 2023, at the State Room in Boston, with programming beginning at 9:00 a.m. ET each day. The Summit will feature frank conversations on vital topics with C-suite industry leaders, and spirited discussions with leading academics and patient advocates on the biggest challenges across health care today.

Key Points: 
  • 2023 STAT Summit will feature leading executives from Eli Lilly, Biogen, GSK, and more, with virtual appearances from Michael J.
  • Fox, Mark Zuckerberg and Priscilla Chan
    BOSTON, Oct. 10, 2023 /PRNewswire/ -- STAT , the leading media company reporting on health, science, and medicine, is set to host its fifth annual flagship event, the 2023 STAT Summit , later this month.
  • The 2023 STAT Summit is presented by St. Jude Children's Research Hospital, and will feature a discussion with James R. Downing, M.D., St. Jude Children's Research Hospital president and CEO.
  • Top executives, key scientists, economists and health outcomes researchers will take the Summit stage to explore solutions together.

Coastal Bridge Advisors, Independent RIA, Celebrates 15 Years of Uncomplicating Wealth Management

Retrieved on: 
Tuesday, October 10, 2023
La, Near, Organization, Law, Human, Environment, Growth, Iskandar Coastal Bridge, UHNW, Justice, HNW, Dana–Farber Cancer Institute, Financial services, Construction

The firm has a mission designed to simplify the complexities of wealth management through its " Uncomplicate It " approach.

Key Points: 
  • The firm has a mission designed to simplify the complexities of wealth management through its " Uncomplicate It " approach.
  • Alongside the financial growth achieved by Coastal Bridge Advisors, this milestone also underscores the invaluable contributions made by its dedicated advisors and team members.
  • Coastal Bridge Advisors has also become an integral part of the Westport and Los Angeles communities by upholding a steadfast commitment to giving back.
  • As Coastal Bridge Advisors looks ahead to the next 15 years, the firm remains committed to delivering individualized wealth management solutions for clients, fostering growth opportunities for teammates, and positively impacting the communities it serves.

Flagler Technologies Expands to The Carolinas Bringing Seamless Technology Integration to Businesses of All Sizes

Retrieved on: 
Thursday, October 5, 2023
Knowledge, New Hire Registry, Dell, Flagler, Fortune 500, Health, Education, University, Entertainment, Dana–Farber Cancer Institute, Dana, University of Massachusetts Amherst

CHARLESTON, S.C., Oct. 5, 2023 /PRNewswire/ -- Flagler Technologies continues its southern United States expansion with the addition of Matt Maypother.

Key Points: 
  • CHARLESTON, S.C., Oct. 5, 2023 /PRNewswire/ -- Flagler Technologies continues its southern United States expansion with the addition of Matt Maypother.
  • Maypother is well versed in the technology world and has proven successful in his many sales roles over the last five years.
  • He has achieved many notable honors, including the New Hire MVP Award and the Fireside Award from Dell.
  • For more information about this appointment, or Flagler Technologies expansion, please visit flagler.io or call (561) 229-1601.

Largest International Assembly on Chronic Lymphocytic Leukemia (CLL) Raises Curtain on 20th Biennial Meeting in Boston, Massachusetts

Retrieved on: 
Tuesday, October 3, 2023
CLL, International Workshop on Lung Health, Abstract, Partnership, Lymphoproliferative disorders, Epidemiology, Court of general sessions, Research, Genomics, Doctor of Philosophy, BTK, Proteomics, Hynes Convention Center, Harvard Medical School, Medicine, Metabolism, MD, Patient, Physician, Hematology, XX, Diagnosis, Chronic lymphocytic leukemia, Leukemia, Health, Social media, Disease, Dana–Farber Cancer Institute, Medical device, Veterinary medicine

BOSTON, Oct. 3, 2023 /PRNewswire/ -- On Friday, October 6, the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) will commence its 20th biennial meeting (XX iwCLL) at the Hynes Convention Center in Boston, Massachusetts. Founded in 1979, iwCLL is the world's leading member-driven organization dedicated to the field of CLL and related lymphoproliferative disorders, bringing together leaders from scientific research, clinical medicine, and the pharmaceutical and biotechnology industries.

Key Points: 
  • BOSTON, Oct. 3, 2023 /PRNewswire/ -- On Friday, October 6, the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) will commence its 20th biennial meeting (XX iwCLL) at the Hynes Convention Center in Boston, Massachusetts.
  • The International Workshop on Chronic Lymphocytic Leukemia hosts its 20th biennial meeting in Boston on Oct. 6-9, 2023.
  • "Recent data from both the laboratory and clinic have reignited the CLL community's enthusiasm and dedication toward finding a cure.
  • The 4-day event will begin on Friday with a Young Investigator Meeting, applicable for individuals early in their hematology careers.

Health Data Analytics Institute (HDAI) Announces $31 Million Funding Round to Scale Predictive Risk Platform

Retrieved on: 
Monday, October 2, 2023
Cleveland Clinic, Population health, Health, Case management (US healthcare system), EVP, Synthetic media, INVU (song), History, Acos, Patient, Physician, Machine learning, Generative, Artificial intelligence, AI, Chamoun, Scale, Dana–Farber Cancer Institute, Medical device, Houston Methodist Hospital

BOSTON, Oct. 2, 2023 /PRNewswire/ -- Health Data Analytics Institute (HDAI)— an artificial intelligence (AI) company focused on empowering clinicians, optimizing care pathways, and improving patient outcomes — today announced an oversubscribed Series C financing to scale its predictive risk platform.

Key Points: 
  • Several preeminent health systems including Houston Methodist, Cleveland Clinic, and Dana-Farber Cancer Institute, are collaborating with HDAI on various initiatives.
  • HDAI has additional collaborations with over 40 Medicare Accountable Care Organizations (ACOs) through which it collectively generates 50 million weekly predictions for one million patients.
  • The platform forecasts health risk at patient, practice, institution and/or regional levels and supports clinicians and institutions in driving performance improvements.
  • Health Data Analytics Institute (HDAI) is a care optimization, decision support and provider enablement company powered by big data, AI-powered analytics, expert insights and point of care technology solutions.

MNA: Dana-Farber Merrimack Valley Nurses to Leaflet Outside Boston Hospital September 29 about DFCI Spending Money on Lock Out After Strike Instead of Investing in Nurses and Cancer Patients

Retrieved on: 
Thursday, September 28, 2023
National Nurses United, State, AOCNP, Legislature, Dana–Farber Cancer Institute, Nursing, DFCI, Workplace, D. Lawrence Kincaid, Brigham and Women's Hospital, Cancer, Multimedia, Movement, Patient, Practitioner, Hospital, Commonwealth, Merrimack, Disease, MNA, Merrimack Valley

BOSTON, Sept. 28, 2023 /PRNewswire/ -- During a lockout inflicted on Merrimack Valley nurses and patients by Dana-Farber Cancer Institute (DFCI) following a one-day strike, nurses will meet outside the DFCI hospital in Boston on Friday, September 29 to leaflet the public and share their concerns about how Dana-Farber executives are spending critical resources.

Key Points: 
  • DFCI – MV nurses and nurse practitioners held a one-day strike on September 27 because DFCI executives refused to make reasonable compromises with nurses to reach a fair contract.
  • Instead of reaching a reasonable compromise with nurses, DFCI is refusing to let nurses back to work following the strike.
  • DFCI executives are spending money on travelers rather than allowing local nurses to care for their patients.
  • DFCI is disaffiliating from Brigham and Women's Hospital and spending millions on a new inpatient hospital.

Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer

Retrieved on: 
Wednesday, September 27, 2023
Oncology, Medical Devices, Health, Health Technology, Research, Science, Genomic Health, University, Brigham and Women's Hospital, Duke University School of Medicine, Cancer, Multimedia, Medicine, Dartmouth College, Dana–Farber Cancer Institute, Reagan-Udall Foundation, Patient, Physician, Mortality, Hospital, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Microbiology, Dana, Nursing, Pharmaceutical industry, Illumina, Biology

Veracyte, Inc. (Nasdaq: VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer.
  • He will report to Marc Stapley, Veracyte’s chief executive officer.
  • View the full release here: https://www.businesswire.com/news/home/20230927846710/en/
    Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer (Photo: Business Wire)
    “Phil is an exceptional leader with a strong track record of driving successful commercialization of molecular tests through evidence development, guideline inclusion and key opinion leader support,” said Mr. Stapley.
  • He most recently served as chief medical officer for Illumina where he built the medical team and led the successful strategy to engage clinical customers.